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ABSTRACT

Pothana, Kartheek. M.S. Department of Pharmacology and Toxicology, Wright State
University, 2020. Low dose UV-B induced keratinocyte exosomes protect Schwann cells
against high glucose injury.

In this study, we tested the protective effect of UV-B treated HG-HaCaT-Exos on Schwann
cells (SCs) injured by HG (high glucose) model. At first, we determined the dose of UV-B
radiation and the time for the release of HaCaT-Exos. Furthermore, the Schwann cells were
injured through the HG model, isolated by ultracentrifugation from the HaCaT cell culture
supernatant were co-incubated within the injured cells. It was found that UV-B treated
HaCaT-Exos decrease apoptosis and increase the viability of injured SC by transferring miR222 from HaCaT cells to them via exosomes, hence protecting them.
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INTRODUCTION

Epidemiology:
Diabetes mellitus (DM) is one of the main health complications in the world. It is estimated
that more than 463 million are diagnosed with diabetes in 2019 according to the International
diabetic federation and expected to reach up to 700 million by 2045. In 2018, the United
States ranks seventh in the leading cause of death related to diabetes mellitus in the world and
seventh among other causes of death within the United States. In Ohio, approx. 1,003,000 are
diagnosed with diabetes which is 11.1% of Ohio’s population and around 33.6% have
prediabetes with a blood glucose level higher than normal. [1]

Figure 1: Epidemiology of Diabetes Mellitus in the world.[82]
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Diabetes mellitus (DM):
“Diabetes mellitus (DM) is a collection of metabolic disorders characterized by chronic
hyperglycemia, glycosuria, hyperlipidemia, and negative nitrogen balance resulting from
defects in insulin secretion and insulin action, or both thus causing a concomitant increase in
both fasting and postprandial blood glucose levels.”[2]

DM is defined as a metabolic disorder that is characterized by hyperglycemia which is caused
by the body’s ability to produce or respond to the hormone insulin for a prolonged period.
Hyperglycemia is the condition in which the blood glucose levels are higher than normal,
which is more than 100 mg/dl of fasting blood glucose levels. [3]

Based on blood glucose levels, the pre-diabetic state is also considered in which the fasting
blood glucose levels are between 100 mg/dl to 125 mg/dl and if the fasting blood glucose
levels are more than 126 mg/dl, then this stage is considered as diabetes. At present, diabetes
mellitus can be diagnosed by three different tests, which are as follows: A1C, Fasting blood
glucose test, and Oral glucose tolerance test (OGTT). [4]

Condition/Test

A1C

Fasting blood

Oral glucose

glucose

tolerance test

Normal

< 5.7%

< 100 mg/dl

< 140 mg/dl

Prediabetic

5.7% to 6.4%

100 mg/dl to 125

140 mg/dl to 199

mg/dl

mg/dl

> 126 mg/dl

>200 mg/dl

Diabetic

>6.5%

Table 2: Tests and levels for diagnosis of DM [79]
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Types of DM:
DM is categorized into two types based on production or response related to insulin, namely,
Type 1 diabetes mellitus and Type 2 diabetes mellitus. [5]

In, type 1 diabetes mellitus, ß-cells that produce insulin are damaged or cannot produce
insulin sufficiently or completely increasing blood glucose levels.

Whereas in type 2 diabetes mellitus, ß-cells can produce insulin, but the insulin receptors are
damaged partially or completely by which the cells couldn’t react to insulin hormone and lose
the ability to absorb blood glucose and cannot utilize the resulting increase in blood glucose
levels.[6]

Figure 2: Types of DM. A) Healthy condition, B) Type 1 DM, C) Type 2 DM. [83]
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Complications of Diabetes mellitus:
A prolonged period of Hyperglycemia (in this case, diabetes) causes damage to many organs
and systems, mainly the nervous system, cardiovascular and excretory system, which results
in many other health complications explicitly neuropathy, nephropathy, Diabetic
ketoacidosis, hyperosmolar hyperglycemic conditions, damage blood vessels, atherosclerosis,
slow wound healing, retinopathy, cardiovascular diseases, coronary and peripheral artery
diseases and more.[7]

Diabetic neuropathy (DN):
DN is one of the main complications of prolonged hyperglycemia (diabetic condition) and
40% of diabetic patients are diagnosed with neuropathy. Neuropathy is a condition in which
the neurons, nerve fibers are damaged and cause them to lose basic neurological functions for
various reasons. It is a microvascular complication in which the blood vessels which supply
necessary supplements required for survival of nerve fiber are damaged due to diabetic
condition. Long term hyperglycemic condition causes exaggerated oxidative stress, excessive
release of cytokines, enhance advanced glycation end products, activation of protein kinase,
lack of oxygen, or hypoxic damage accelerating endoneurial microangiopathy and apoptosis
of nerve fiber resulting in DN. [8]
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Figure 3: Condition of nerve fiber and blood vessel in healthy and under diabetic
neuropathy conditions. [84]

DN is of two types based on the type of nervous system it affects, which are peripheral
neuropathy causing damage or loss of peripheral nerves and causes tingling, loss of pain,
numbness mainly in hands and feet, and autonomic neuropathy which disrupts basic body
functions. [9]

SCHWANN CELLS:
Despite the damage of nerve fibers, neurons have a repairing and regeneration unit called
Schwann cell (SC). SC is the collagen-rich, vascularized extracellular matrix linked to the
basal lamina surrounding each axon providing protection and for faster nerve impulse.[10,11]
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Figure 4: Transverse section of peripheral nerve with its components.[86]
Glial cells of early embryonic nerves are the precursors of SC and endoneurial fibroblasts.
Immature SC has control over nerve fasciculation and helps in the survival of motoneurons
and dorsal root ganglia. SC first, up-regulates paracrine neurotrophic substances such as
nerve growth factor (NGF), brain-derived neurotrophic agents (BDNF), artemin, NT3,
VEGF, and pleiotrophin and with the help of supportive cells like fibroblast initiates the
process of axonal repair and/or regeneration of axon. Secondly, regulates cytokine expression
such as tumor necrosis factor (TNF)-α, LIF, interleukin (IL)-1α, IL-1β, LIF, and MCP-1with
macrophages, and finally, breakdown myelin by autophagy to promote cell repair (axonal
repair).[12,13]

ULTRAVIOLET RADIATIONS (UVR):
UVR is one of the electromagnetic radiations emitted from the sun and comprises about 10%
of total radiation. These radiations lie in the 100-400 nm range with-in the total spectrum of
solar radiation. The quality, quantity, and type of UVR varies with the weather, ozone layer,
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air pollution, elevation, time of day, season, and latitude. There are three types of UV
radiations, namely
UV-C (100-280 nm) which is blocked by the ozone layer, so no or very little amount of it
reaches the earth’s surface and it is mostly used for sterilization purposes,
UV-B (280-315 nm) is mostly removed by the ozone layer and this part of the radiation is
responsible for skin burns and major skin cancers,
and UV-A (315-400 nm) is unobstructed by ozone and it is used in skin tanning machines
with some regulations of about 11 J/m2 standard erythema dose (SED) {1SED = 100 J/m2} or
0.3 W m-2 erythema-weighted irradiance level by European Union (EU).
Among 10% of total solar UVR, up to 95% UV-A and 5%, UV-B reaches human
skin.[14,15,16,17]

Figure 5: Wavelength and penetration levels of different ultraviolet radiations. [85]
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Properties of UVR:
The effect of UVR on human health depends on the type and exposure of radiation to the
body. It plays an important role in the synthesis of vitamin D, hence insufficient exposure to
UVR results in osteomalacia, rickets, osteoporosis, autoimmune disorders, sclerosis, obesity,
high risks of cardiovascular complications, type 1 diabetes mellitus. However, it is evident
that UVR is known to cause pigmentation, photo-aging, solar lentigines, wrinkles, tumors,
damage of DNA leading to the death of epidermal cells, and skin cancers. [18,19].
Despite the harmful effects of UVR, it is also used in healthcare as a treatment for many skin
conditions such as psoriasis, atopic eczema. As recent research on UVR had shown to have
beneficial effects on/from molecular levels [20]. It is evident that low and repeated doses of UVR

enhance adaptive immunity by (Norvel.M et al). Exposure to a specific dose of solar UVR is
shown to increase the levels of liver triglycerides and prevent the early signs of
cardiovascular diseases as demonstrated by A.L. Ferguson et al., in mice. [21]

SKIN
Skin is the largest organ of the body, protecting the body from the external environment,
reduce water loss, and thermoregulation. It is composed of three layers namely, epidermis
consisting of keratinocytes and dendrite cells, the dermis is integrated with nerve endings,
vascular networks, fibroblasts, macrophages, mast cells, and other blood cells and
subcutaneous tissue.[22]
Diabetes mellitus affects various organs including skin causing many dermatological
complications including diabetic foot ulcer caused by diabetic neuropathy, acanthosis
nigricans, diabetic dermopathy, scleroderma-like skin changes, ichthyosiform, xerosis,
pruritus, eruptive xanthomas, bullosis diabeticorum, and many more.[23,24,25]
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Nerve bundles are associated with arterioles and venule in the dermal layer. Meissner
corpuscles are responsible for the sense of touch, large nerve ends of Vater-Pacini corpuscles
responsible for the sense of pressure and sense of pain, temperature, the itch was transmitted
by unmyelinated nerve fibers. These nerve fibers were damaged or degenerated by diabetes
conditions leading to diabetic neuropathy. [26,27]

Figure 6: Anatomy of skin and nerve rooting in the layers of skin.[80]

EXOSOMES
Exosomes are one of the phospholipid bilayer extracellular vesicles ranging from 30-100 nm
in size and smallest among other extracellular vesicles including micro-vesicles and apoptotic
bodies. These vesicles were discovered around three decades back and undergo biogenesis
within cells and are released into extracellular space by almost all cells under normal or
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stressed condition of cells. As they were synthesized and released by most of the cells, they
are found in all biological fluids like saliva, blood, cerebrospinal fluid, semen, and urine.
[28,29,30,31,32].

Figure 7: Exosomes released by Epstein– Barr virus-transformed B cell under
Transmission Electron Microscopy [45].

Exosomes were assumed to be cell debris which played an important role in discarding
unwanted cellular components from the cellular environment at the early discovery, but later
researches had proved that these are responsible for intercellular communication by carrying
various components of one cell to another. [33,34]

Biogenesis and Composition
As mentioned before that exosomes were formed within the cells with a series of steps
starting with the early endosome by inward budding of the plasma membrane. These early
endosomes mature into late endosomes also known as multivesicular endosomes (MVEs)
with intraluminal vesicles (ILVs). The MVEs release ILVs into the extracellular environment
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by fusing with the plasma membrane, these released ILVs are denoted as exosomes.
[35,36,37]

Figure 8: Exosome biogenesis. A brief insight into the exosome biogenesis within a cell
and their release in the extracellular space. [69,70].

During the maturation of endosomes which is before the generation of MVEs, cargo is sorted
within the endosomes which is responsible for the overall content of exosomes and this
decides the function of exosomes. Cargo sorting is structured by either the Endosomal
Sorting Complex Required for Transport (ESCRT) mediated pathway or Ceramide dependent
pathway [38, 39,40,41]. They are interchangeably known as non-ESCRT dependent pathways
or non-ceramide pathways respectively. The ESCRT mediated pathway is integrated with
four components that are responsible for different functions involving cargo sorting, viz.
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ESCRT-0, I, II, and III. Ceramide-dependent pathway contains lipid rafts which are glycollipoprotein microdomains. Nevertheless, the function of the exosomes is decided by the cargo
of the parent cell from which these are formed. Exosomes were reported to contain mainly
mRNA, miRNA, DNA, lipids, proteins, etc. [42,43,44,45].

Figure 9: Exosome composition. Exosomes are composed of a varied collection of
biomolecules such as the mRNA, miRNA, DNA, proteins, and lipids
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Isolation
Over the years, various methods were discovered to isolate the exosomes with their own
merits and demerits. Some of the established methods are the gold standard method of
ultracentrifugation technique or differential centrifugation (which I widely used), density
gradient centrifugation, filtration, size exclusion chromatography, polymer-based
precipitation, sieving, and immunological separation. [68,69,70].

Detection and Characterization
Isolated exosomes can be analyzed by various methods to determine their morphology,
quality, concentration, and size. These methods can be categorized into biophysical,
antibody-based, and optical methods. Nanosight Tracking Analysis (NTA), scattering flow
cytometry (SFC), fluorescence microscopy, and dynamic light scattering (DLS) are held in
optical methods. Various EX specific antibodies and arrays are available which are detected
by FACS/flow cytometry or ELISA. And the biophysical methods consist of scanning
electron microscopy (SEM), transmission electron microscopy (TEM), and atomic force
microscopy (AFM) [71,72,73,74,75,].

Exosome uptake
Literature and studies have suggested that there is more than one pathway or mechanism
for the uptake of Exos by the cells. However, this uptake is a characteristic of the recipient
cell rather than the donor cell. In recent years, more studies are being conducted to
know more about the uptake pathways and their unique characteristics. The uptake
pathways are broadly classified into membrane fusion and endocytosis. Major uptake is
carried out via the endocytic mechanism. Endocytosis is further classified into
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phagocytosis, macropinocytosis, clathrin-mediated endocytosis, caveolin-mediated
endocytosis, lipid-raft mediated endocytosis, and receptor-mediated endocytosis [77,78,79].

Figure 10: Pathways participating in Exos uptake. [78]

Function
Studies have suggested that Exos are involved in cellular signaling, wherein they carry
information in the form of biomolecules from the parent cell to the recipient cell. This
remains to be the unique function of Exos. Along with this, they are involved in the
facilitation of immune response, angiogenesis, wound healing, inflammation, and coagulation
[57].
They are also considered to be biomarkers in the diagnosis and prognosis of various medical
conditions and have proved to have immense diagnostic potential over the years. However,
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the most important property of Exos, which has gained some limelight over time, is that
they can act as therapeutic agents and drug delivery carriers. The reason being the cargo
present in these vesicles which are then expelled into the recipient cell for its benefits.
This cargo can then provide the required therapy. Although, the cargo either depends on
the parent cell or if it has been edited for specific drug delivery [58,59,60].

MicroRNA-222:
MicroRNA are 21-25 base pair long non-coding RNA and are highly expressed in human
hematopoietic progenitor cells, human umbilical vein endothelial cells, HaCaT cells, and
Schwann cells. miR-222 is located on chromosome Xp11.3. It has been reported by Uyen
T.T. Than et al., that miR-222 is abundantly expressed abundantly in exosomes compared to
microvesicles and apoptotic bodies secreted from HaCaT cells. [61,62,63,64]
It is estimated that the target of miR-22 is were not exactly reported and believed to act
indirectly via gene expression, translation efficiency, or post-translational pathway. However,
it is stated that miR-222 acts on the p27 factor. It is evident that miR-222 promotes Schwann
cell proliferation and migration, proven by Ching. R.C. et al.[65]
miR-222 is involved in angiogenesis, proliferation, cell migration, and DNA damage
response. It is observed that the overexpression of miR-222 in PC3 cells had altered the
growth rate by causing a shift from the G1 to S phase of the cell cycle. [66,67]
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Figure 11: A) Stem-loop structure of miR-222, B) Genomic location of miR-221 and miR222 on chromosomal band Xp11.3 [81]
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HYPOTHESIS AND SPECIFIC AIMS

HYPOTHESIS
Low dose UV-B modulates the release of exosomes from Keratinocytes under high glucose
(HG) conditions which provide protective effects on Schwann cells (HG).

SPECIFIC AIMS:
Aim 1: To determine whether UV-B modulates the release of Exos from Keratinocytes under
high glucose (HG) conditions.
Aim 2: To evaluate if exosomes from Keratinocytes under high glucose (HG) condition &
low-dose UV-B treatment, show a protective effect on Schwann cells in high glucose (HG)
condition.
Aim 3: To determine the Exos uptake into Schwann cells by targeting uptake mechanisms.
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EXPERIMENTAL DESIGN

Design for Aim 1:
1a. HaCaT cells were cultured and allowed to be 70% confluent, then treated with UV-B
radiation in hanks balanced salt solution (HBSS), followed by serum starvation for 0, 4, and
24 hours. The culture media was collected for Exos isolation, followed by nanoparticle
tracking analysis (NTA) to determine a time interval for the maximum number of exosome
isolation. HaCaT cells at passages 55-65 were used for this study.

1b. HaCaT cells were cultured and allowed to be 70% confluent, then they were treated with
25mM D-glucose with complete media for 24 hours, followed by UV-B radiation treatment
of low dose consisting of 50J/m2, 100J/m2, and a high dose of 900J/m2, 1800J/m2 with an
untreated control in HBSS, followed by serum starvation for 24 hours. The culture media was
collected for Exos isolation, followed by NTA of exosomes, and cells are collected and
counted using trypan blue assay.

1c. RNA was isolated from HaCaT Exos, converted to cDNA by RT-PCR, followed by
qPCR.

18

Figure 12: Experimental design for aim 1.
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Design for Aim 2:
2a. Schwann cells (SC) were cultured and allowed to be 60% confluent, then treated with
75mM D-glucose, and 25mM D-glucose with 250mM L-palmitate in respective SC plates
along with a control group for 48 hours after which Hoechst stain and MTT assays were
performed. SCs at passages 2-6 were used for this study.

Figure 13: Experimental design for aim 2. Establishing cell injury model of SC.

2b. HaCaT cells were cultured and allowed to be 70% confluent, then they were treated with
25mM D-glucose with complete media for 24 hours, followed by UV-B radiation treatment
in HBSS, followed by serum starvation for 24 hours. The culture media was collected for
Exos isolation, followed by NTA of Exos. These HaCaT-Exos were resuspended in Schwann
cell (SC)media. Schwann cells were cultured and allowed to be 60% confluent and incubated
with 25mM D-glucose and 250µM L-palmitate in SC complete media for 48 hours. After this
20

these culture plates and incubated for 24 hours after which MTT assay and qPCR were
performed.

Figure 14: Experimental model of aim 2. Effect of UV-B treated HG-HaCaT Exos on HGSCs.
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Design for Aim 3:
HaCaT cells were cultured and allowed to be 70% confluent followed by serum starvation for
24 hours. The culture medium was collected for Exos isolation. The obtained HaCaT-Exos
were fluorescently labeled with PKH26 and resuspended in SCs medium. On the other hand,
the SCs were cultured and grown till 80% confluency followed by treatment with vehicle,
80μM Dynasore, 10μM Pitstop 2, 200μM Genistein, or 5μM LY294002 for 30 minutes. The
cells were then washed and the labeled HaCaT-Exos were added for 24 hours. The
mechanism of uptake was determined by obtaining fluorescent images.

Figure 15: Experimental design for aim 3. Determination of dominating the uptake
mechanism of Exos exhibited by SCs.
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MATERIALS AND METHODS

Human keratinocyte cell line and Schwann cells were purchased from ATCC. Culture media
for both the cell lines were purchased from Hyclone, Utah. Heat inactivated Foetal bovine
serum, 0.25% trypsin EDTA, L-glutamate, Penicillin, and streptomycin were purchased from
Gibco (Thermofisher scientific), PKH26, PKH67, (D)-glucose, and L-palmitate were
purchased from Fisher scientific. miR-222 primers were ordered from Sigma Millipore,
TRIzol reagent, chloroform, were purchased from Invitrogen (Carlsbad, CA). Dynasore
hydrate was purchased from Sigma-Aldrich (St. Louis, MO). LY294002 was purchased from
Enzo (Farmingdale, NY). Genistein was purchased from EMD Millipore (Israel). Pitstop 2
was purchased from Abcam (UK).

Cell culture
HaCaT cells and Schwann cells (SCs) were used in this study. HaCaT cells were cultured
using DMEM high glucose media with 10% fetal bovine serum (FBS) with 1% L-glutamine
and Pen Strep in an incubator with maintaining 37ºC and 5% CO2 conditions. Culture media
is replaced every 2 days. HaCaT cells are at passage 57-78 were used in this study
SC was cultured using DMEM high glucose with 10% fetal bovine serum (FBS) and 1% Lglutamine and 1% Antibiotic and antimycotic agents, in an incubator with maintaining 37ºC
and 5% CO2 conditions. SCs are at passage 2-6 were used in this study. For passaging HaCaT
cells,70% confluency was maintained, and for SCs 60% confluency. Later, the cell plate
media was replaced with 0.05% trypsin EDTA at 37°C for 10 and 5 minutes for HaCaT cells
and SCs, respectively. Serum media is added to stop the trypsinization process then collected
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and centrifuged at 300x g for 8 minutes, the pellet obtained is resuspended in culture media
and passaged at 1:7 and 1:4 ratio, respectively.

Exosome isolation
HaCaT cells were cultured in a serum-free medium for 24 hours. After serum starvation, the
culture medium was collected and centrifuged at 300 x g for 8 minutes, followed by 2000 x g
for 20 minutes to remove the cells along with cell debris. The obtained supernatant was
centrifuged at 20,000 x g for 70 minutes, this allowed the pelleting of microvesicles (MVs).
As we do not make use of the MVs in our study, the obtained supernatant was subjected to
ultracentrifugation at 170,000 x g for 90 minutes to pellet the Exos [69]. After
ultracentrifugation, the supernatant was discarded, and the pellet was resuspended in 100μl
sterile-filtered phosphate buffer saline (PBS).

Nanoparticle tracking analysis (NTA)
The size and concentration determination of the isolated HaCaT-Exos was carried out by the
instrument NS300 (Nanosight, Amesbury, UK). NTA visualizes and measures particle size
and concentration by utilizing light scattering and Brownian motion properties. It can detect
the size distribution of particles in solution from 10nm to 2μm in diameter. The optimum
particle concentration detected by NTA is ~107-109 particles/ ml. For better detection, the
Exo samples were diluted with sterile-filtered PBS to a concentration of 107-108 particles/ml.
After diluting the sample, 700 μl of the same was loaded in the instrument for movement
tracking at the rate of 30 frames/ second. The videos with particle movement were recorded
at least 3 times per sample at different positions which were analyzed by the NTA software
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(version 2.2, Nanosight). The NTA results were produced as a mean of the 3 tests performed
per sample and the particle concentration was calculated after considering the accurate
dilution factor for the NTA results.

Exosome labeling
To label the Exos, PKH26, or PKH67, lipophilic-membrane dyes exhibiting red or green
fluorescence respectively were used. The isolated Exos was added to a solution of 2μl dye in
1 ml PBS for 5 minutes. To stop the reaction, 1ml 1% BSA was added and allowed to stand
for a minute. This was then ultracentrifuged at 170,000 x g for 90 minutes, to obtain the
fluorescent (PKH26 or PKH67) labeled Exos pellet. The supernatant was discarded, and the
pellet was resuspended in SC medium for further co-incubation with the cells.

Cell Injury model of HaCaT cells (High glucose [HG] model)
The injury model in this experiment includes high glucose (HG), as an invitro representation
of diabetes mellitus. For including HG injury, the HaCaT cells were cultured at a confluency
of 70% and treated with 25mM D-glucose in complete media for 24 hours in the incubator at
37ºC with 5% CO2 conditions. Later, these cells were treated with UV-B radiation.

UV-B treatment.
HaCaT cells were cultured at 70% confluency, then the media was replaced with HBSS and
the plate is placed under direct UV-B light with an open lid and immediately replaced with
serum starvation media for 24 hours in the incubator at 37ºC with 5% CO2 conditions. Later
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the media is collected for isolation of exosomes and cells for trypan blue assay or PCR. Or
for further co-culture with SCs.

Cell injury model of Schwann cells (High glucose [HG] model)
The injury model in this experiment includes high glucose (HG), as an invitro representation
of diabetes mellitus. For including HG injury, the SCs were cultured at a confluency of 60%
and treated with 25mM D-glucose and 250µM L-palmitate in complete media for 48 hours in
the incubator at 37ºC with 5% CO2 conditions.

Co-incubation of HaCaT Exos with SCs
The isolated exosomes were resuspended in SC complete medium and added to the cells as
per the experimental design. The HaCaT Exos are co-cultured at 1 x 109 and 2 x 109 Exos
particles per ml concentrations in complete SC medium and incubated for 24 hours.
Following this, fluorescence was recorded, or MTT assay or PCR is performed.

Exosome uptake mechanism determination
There are many pathways considered for the uptake of Exos by the recipient cell and were
believed to vary from different cell lines. To determine the HaCaT-Exos uptake by SCs, we
concentrated on the endocytic uptake restricting it down to endocytosis, Clathrin-mediated
endocytosis, caveolin mediated endocytosis, macropinocytosis. Specific concentrations of
inhibitors for the respective uptake pathways were treated to the cells for 30 minutes. The
inhibitors include 80μM Dynasore (endocytosis/dynamin inhibitor), 10μM pitstop-2 (clathrin-
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mediated endocytosis inhibitor), 200μM genistein (caveolin mediated endocytosis inhibitor),
5μM LY290042 (macropinocytosis inhibitor). Further, the cells were washed twice with PBS
and labeled HaCaT Exos were co-cultured with SCs for 24 hours, followed by fluorescence
microscopy for images.

miR-222 expression analysis
miR-222 from HaCaT Exos was extracted using TRIzol reagent. The collected exosomes and
cells were treated with 1ml TRIzol reagent in a 1.5ml tube and let sit for a minute. 100µl of
chloroform is added to this tube and shaken for 15 seconds till the solution turns pink. Tubes
were set aside for 10 minutes at room temperature and centrifuged at 12,500xg for 15 minutes
at 4ºC. The tube solution is separated into three layers, with RNA in clear liquid on the top, a
pink solution with cell debris at the bottom, and a white middle layer of DNA. Carefully the
upper colorless RNA layer is separated into another 1.5ml tube, to this 500µl of precooled
isopropanol was added, mixed, and allowed to rest at -20ºC for 10 minutes, followed by
centrifugation at 12,500x g for 15 minutes at 4ºC,. The supernatant was discarded, and the
pellet is washed with 21ml of 75% ethanol. The tube was centrifuged at 7500x g for 5
minutes at 4ºC. The supernatant is discarded and let the tube is dried in a ventilation hood for
a minimum of 10 minutes. The obtained RNA is eluted with 10µl and 30µl of double distilled
water for Exos and cells, respectively. The concentration of RNA was measured using
Nanodrop-2000 equipment. cDNA was synthesized using PrimeScript RT reagent kit (Takara
Bio Inc.) following the manufacturer’s instructions. qRT-PCR was carried out using miR-222
specific primers and SYBR Premix Ex Taq kit (Takara Bio Inc.) on a real-time PCR
instrument (Bio-Rad), while RNA U6 was used as an internal control for this determination.
Expression of miR-222 was calculated using the 2−ΔΔCT method.
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The same procedure is applied for the HG SCs co-cultured with UV-B treated HG HaCaT
exosomes, to determine the fold change of miR-222 expression.

Cell viability assay
Cell viability was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT). In this assay, MTT is converted to formazan which in turn is determined by optical
density at 540 nm. To perform this assay, SCs were cultured in 96 well plates at 100%
confluency. Triplicates were maintained as per the manufacturer’s instructions. After the
treatment when the SCs are ready for assay, the media is replaced with 100µl fresh media,
and to each of the wells, 10µl of 12mM MTT solution was added and mixed well, then
incubated for 2 hours. Later 85µl of the media is discarded, leaving 25µl in the wells. 50µl of
DMSO is added, mixed by vigorous pipetting, and incubated at 37ºC for 10 minutes. The
samples were mixed again, and absorbance is read at 540nm.
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RESULTS
UVB promotes HaCaT-EXOSOME RELEASE in a TIME DEPENDENT
manner
For the time-dependent based study of exosome release of HaCaT cells, HaCaT cells were
cultured in complete media till 80% confluent and then incubated with serum-free media for
3 different time points 0 hours, 4 hours, and 24 hours with and without prior UV-B treatment.
Isolated exosomes were analyzed by NTA to exosome particles released per HaCaT cell. As
it is observed in (Fig 16:A) exosome release increased as the time prolongs and with UV-B
radiation of dose 100J/m2, as shown in the graph (Fig 16:B), exosome release follows the
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Figure 16: Time-dependent release of HaCaT-Exos. A) Data summary representing the
time-dependent release of HaCaT cell Exos., B) Data summary representing time-dependent
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release exosomes of HaCaT cells treated with 100J/m2 of UV-B radiation. Data are
represented as mean ± SEM. n=4 for control-0hrs, n=4 for 4 hrs, n=4 for 24 hrs. *: P<0.05

UV-B stimulates HaCaT-exosome release in a dose-dependent manner, with a
prominent effect in HG condition
To determine the release of Exos from UV-B treated HaCaT cells, of two groups which are
normal glucose (NG) and high glucose (HG). Each group of HaCaT cells was treated with
different doses of UV-B radiation including 50 J/m2, 100 J/m2, 900 J/m2, 1800 J/m2 along
with control or no UV-B radiation treatment group. After serum-free media incubation of
HaCaT cells for 24 hours, the Exos were isolated and analyzed with NTA. It was observed
that the Exos release from HaCaT cells increases as the dose of UV-B radiation increase in a
dose-dependent manner in both the NG groups and high glucose HG groups. And the Exos
release of HG is higher than that of subsequent NG groups.
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Figure 17: Release of HaCaT Exos with UV-B treatment in NG and HG groups. The data
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above represents the Exos released from HaCaT cells after treatment by 50 J/m2, 100 J/m2,
900 J/m2, and 1800 J/m2 doses of UV-B radiation under NG and HG conditions, followed by
incubation for 24 hours with serum-free media. Data are represented as mean ± SEM. n=4 for
control, n=4 for 50J/m2, n=4 for 100J/m2, n=3 for 900J/m2, n=3 for 1800J/m2. *P<0.05.,
**P<0.01, ***P<0.001

UVB decreases HaCaT cell viability in HG condition
To determine the cell viability of UV-B treated HaCaT cells, of both NG and HG groups.
Each group of HaCaT cells was treated with different doses of UV-B radiation including 50
J/m2, 100 J/m2, 900 J/m2, 1800 J/m2 along with control or no UV-B radiation treatment
group. After serum-free media incubation of HaCaT cells for 24 hours, the Exos were
isolated and the cells were collected with trypsin and analyzed with trypan blue assay. It was
observed that the cell viability of HaCaT cells decreased as the dose of UV-B radiation
increase in the following dose-dependent manner in both the NG groups and high glucose HG
groups.

31

✱✱✱
✱✱

ns
ns
✱

Cell viability(%)

100
80
60
40
20
0

UV-B dose (J/m2)

NG HG

NG HG

NG HG

NG HG

Control

50

100

900

NG HG

1800

.

Groups

Figure 18: Cell viability of HaCaT Exos with UV-B treatment in NG and HG groups. The
data above represents the cell viability(%) of HaCaT cells after treatment by 50 J/m2, 100
J/m2, 900 J/m2, and 1800 J/m2 doses of UV-B radiation under NG and HG conditions,
followed by incubation for 24 hours with serum-free media. Data are represented as mean ±
SEM. n=4 for control, n=4 for 50J/m2, n=4 for 100J/m2, n=3 for 900J/m2, n=3 for 1800J/m2.
**P<0.01, ***P<0.001

UV-B promotes miR-222 package into HaCaT exosomes
To determine the transfer of miR-222 from the HaCaT cell to their released exosomes, RNA
was extracted from isolated HaCaT-Exos and were analyzed by qRT-PCR. The levels of
miR-222 in UV-B treated HaCaT-Exos were found to be around 20, 30, 500, and 200 folds in
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NG-100J/m2, HG-100J/m2, NG-1800J/m2, and HG-1800J/m2 groups respectively in

Fold change(Expression of miR-222)

comparison with untreated NG HaCaT-Exos control.
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Figure 19: Expression of miR-222 in UV-B treated HG HaCaT-Exos. Expression of miR222 was analyzed with qRT-PCR in exosomes released from HG HaCaT cells treated with
different UV-B doses. Data are represented as mean ± SEM. n=7 for control, n=7 for 100J/m2
n=3 for 1800J/m2.

Establishing an injury model (diabetic condition) of Schwann cell
To establish the HG injury model in SCs, SCs were treated with 75mM D-glucose and 25mM
D-glucose with 250µM L-palmitate in complete media for 48 hours, followed by Hoechst
stain and MTT assay to analyze apoptosis. As in (Fig:17A) the DNA in the nucleus is stained
with Hoechst stain. Groups included are control, 75mM D-glucose media, and 25mM Dglucose + 250µM L-palmitate in complete media. The condensation of DNA is observed
under a fluorescent microscope at 40X magnification. The nucleus of control as in
(Fig:20A[i]) is considered normal and healthy. SCs treated with 75mM D-glucose have
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acquired an abnormally shaped nucleus with no to a small amount of DNA condensation as
shown in (Fig 20A[ii]). And the nucleus which is exposed to 25mM D-glucose + 250µM Lpalmitate is distorted and DNA condensation is observed as indicated in (Fig:20A[iii]). The
absorbance at 540nm is recorded to analyze the cell viability of groups by MTT assay
mentioned above (Fig:20B).
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Figure 20: Establishing injury model (diabetic condition) of Schwann cell.
A) Representative Hoechst staining fluorescent images exhibit DNA condensation.
i) Control, ii) 75mM D-glucose, iii) 25mM D-glucose + 250µM L-palmitate. B) Summarized
MTT assay representing Absorbance at 540nm. Data are represented as mean ± SEM. n=4 for
control, n=4 for 75mM glucose, n=4 for 25mM glucose + 250µM L-palmitate, *P<0.05,
***P<0.001.

Co-culture with low-dose UV-B treated HG HaCaT exosomes raised miR-222
level in HG Schwann cells
To determine the transfer of miR-222 from the HaCaT-Exos into HG SCs, RNA was
extracted from HaCaT-Exos treated SCs and were analyzed by qRT-PCR. The levels of miR222 in HG-SCs + HG HaCaT-Exos-100J/m2 was found to be higher by around 2 and 3.5
folds when co-cultured with 1 x 109 Exos per ml and 2 x 109 Exos per ml, respectively,
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comparison with untreated NG-SCs, and 0.5, and 2 fold increase when compared with
untreated HG-SC group at 1 x 109 Exos per ml and 2 x 109 Exos per ml, respectively.
Whereas fold change expression of miR-222 in HG-SCs + HG HaCaT-Exos-1800J/m2 was
found to have no change or slight increase compared to NG-SCs and HG-SCs group and
lower expression levels when compared with SCs + HG HaCaT-Exos-100J/m2 group in
irrespective of Exos dose.
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Figure 21: Expression of miR-222 in SCs co-cultured with UV-B treated HG HaCaT-Exos.
Summarized data showing the fold change levels of expression of miR-222 in SCs cocultured with UV-B treated HG-HaCaT-Exos. SC-NG: SC-normal glucose, SC-HG: SC-high
glucose, SC-HG + HaCaT Exo HG-100: HG-SCs co-cultured with HG-HaCaT-Exos-UVB100J/m2, SC-HG + HaCaT Exo HG-1800: HG-SCs co-cultured with HG-HaCaT-Exos-UVB1800J/m2, A) SCs were co-cultured with 1 x 109 Exos per ml, B) SCs were co-cultured with 2
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x 109 Exos per ml. Data are represented as mean. n=3 for SC-NG, n=3 for SC-HG, n=3 for
SC-HG + HaCaT Exo HG-100, n=3 for SC-HG + HaCaT Exo HG-1800.

Co-culture with low-dose UV-B treated HG HaCaT exosomes improved the
viability of Schwann cells in HG condition
To determine cell viability of HG-SCs co-cultured with UV-B treated HG HaCaT-Exos
absorbance is measured in MTT assay. The absorbance levels in HG-SCs + HG HaCaTExos-100J/m2 were found to be higher when co-cultured with both doses of Exos in
comparison with untreated NG-SCs and HG-SC group at 1 x 109 Exos per ml and 2 x 109
Exos per ml. Whereas cell absorbance in HG-SCs + HG HaCaT-Exos-1800J/m2 was found to
have no change or slight decrease compared to NG-SCs and HG-SCs group and lower
absorbance levels when compared with SCs + HG HaCaT-Exos-100J/m2 group in
irrespective of Exos dose.

38

✱✱

0.6

Absorbance (540nm)

A)

✱

0.4

0.2

0.0

SC
HaCaT EXO

NG

HG

HG

HG

-

-

HG
100

HG
1800

Groups

✱

✱✱✱

0.8

Absorbance (540nm)

B)

0.6
0.4
0.2
0.0

SC
HaCaT EXO

NG

HG

HG

HG

-

-

HG
100

HG
1800

Groups

Figure 22: Cell viability of SCs co-cultured with UV-B treated HG HaCaT-Exos.
Summarized data showing the absorbance levels at 540nm in SCs co-cultured with UV-B
treated HG-HaCaT-Exos. SC-NG: SC-normal glucose, SC-HG: SC-high glucose, SC-HG +
HaCaT Exo HG-100: HG-SCs co-cultured with HG-HaCaT-Exos-UVB-100J/m2, SC-HG +
HaCaT Exo HG-1800: HG-SCs co-cultured with HG-HaCaT-Exos-UVB-1800J/m2, A) SCs
were co-cultured with 1 x 109 Exos per ml, B) SCs were co-cultured with 2 x 109 Exos per
ml. Data are represented as mean ± SEM. n=3 for SC-NG, n=3 for SC-HG, n=3 for SC-HG +
HaCaT Exo HG-100, n=3 for SC-HG + HaCaT Exo HG-1800, *: P<0.05, **: P<0.01,
***P<0.001
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Endocytosis pathway dominates exosome uptake pathways in Schwann cells
To determine the Exos uptake mechanisms of SCs, SCs were treated with the inhibitors of
specific uptake mechanism pathway. The pathways focused to include, endocytosis or
dynamin pathway, clathrin-mediated endocytosis, caveolin induced endocytosis, and
macropinocytosis. It is observed that the HaCaT-Exos uptake by SCs is significantly reduced
when treated with inhibitors in comparison to control. SCs were treated with 80μM Dynasore
(dynamin/endocytosis inhibitor), 200μM Genistein (caveolin-dependent endocytosis pathway
inhibitor), 5μM LY294002 (macropinocytosis inhibitor), and 10μM Pitstop 2 (clathrinmediated endocytosis pathway inhibitor) along with vehicle for 30 minutes prior co-culture
with HaCaT-Exos. Fluorescence images were captured after 24 hours of incubation with coculture of HaCaT-Exos which were stained with PKH26 (Fig:23A). The red fluorescence
intensity suggests the uptake of HaCaT Exos by SCs hence, the inhibition of uptake had
occurred after the inhibitor activity. The fluorescent intensity has been recorded in (Fig:23B).
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Figure 23: Mechanisms of uptake for HaCaT-Exos by SCs. A) Representative fluorescent
images of PKH 26 labeled HaCaT-Exos merged with SCs after 30 minutes treatment by
vehicle, 80μM Dynasore, 200μM Genistein, 5μM LY294002, and 10μM Pitstop 2 for an
incubation period of 24 hours. B) Fluorescence intensity levels were recorded and analyzed in
ImageJ. Data are represented as mean ± SD. n=3 for control, n=3 for Dynasore, n=3 for
Genistein, n=3 for LY294002, n=3 for Pitstop-2. ***P<0.001, ****P<0.0001

42

DISCUSSION
Exos are nanosized, phospholipid bilayer extracellular vesicles released by almost all types of
cells in physiological and mostly in stressful conditions. These are synthesized within the
endosomes of the cells and released into the extracellular environment by fusing with the
plasma membrane. Exos are involved in cell-to-cell signaling and found to contain DNA,
RNA, mRNA, miRNA, proteins, lipids, enzymes, and metabolites, which are responsible for
the transfer of information. The function of Exos only depends and varies according to the
type and present condition of the parent cell. With such property and functions, they were
considered and used as a novel therapeutic agent, qualifying for them to be involved in drug
delivery. In the present study, we isolated the Exos from HG-HaCaT cells by treating them
with different doses of UV-B radiation including 50J/m2, 100J/m2 as low dose, and 900J/m2,
1800J/m2 as high dose. Our objective is to select a dose such that it can enhance the release of
Exos and act safely on HaCaT cells as well. It was found that the Exos release from HaCaT
cells time-dependent (Fig 16) and dose-dependent (Fig 17). From summarising the result of
the trypan blue assay, it was confirmed that the cell death/cell viability of HaCaT cells are
dose-dependent to UV-B radiation (Fig 18) as the dose of UV-B radiation increased, the cell
viability decreased. Based on the results of (Fig 16, 17, and 18), 24 hours is selected for the
incubation of exosome release of HaCaT cells, a single dose of UV-B was chosen based on
the results of Exos release and cell viability, in which 100J/m2 from low dose was found to be
increasing the release of Exos and acting safely on HaCaT cell viability, and 1800J/m2 was
selected as a treatment in high dose. This UV-B treated HG-HaCaT Exos were uptaken by
HG-SCs via clathrin-mediated, caveolin mediated endocytosis, macropinocytosis, and
majorly by endocytosis (Fig 23).
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The in-vitro representation of diabetes/high glucose (HG) was achieved through HG-induced
injury of HaCaT cells, 25 Mm D-glucose enriched medium incubation of 24 hours correlates
with the physiological conditions of diabetes/HG based on previous studies. Whereas in SCs,
only D-glucose doesn’t happen to show any physiological conditions of diabetes/HG,
therefore along with 25mM D-glucose, 250µM L-palmitate was added for 48 hours to
facilitate the expected HG injury and was analyzed with DNA staining and MTT assay along
in comparison with 75mM D-glucose concentration and control. As results (Fig 20 A and B)
represent that SCs were undergone apoptosis by damage due to glucose along with palmitate
is high when compared with control and its competitive group consisting of 75mM glucose,
indicating physiological diabetes in SCs.
We also expect the HaCaT-Exos to carry miR-222 within them and it was confirmed from the
analysis of HaCaT-Exos with qRT-PCR, indicating an increase in several expression folds of
miR-222 in different groups. With the summarised results, we can say that UV-B promotes
miR-222 package into HaCaT-Exos (Fig 19), but the fold expression of miR-222 in HGHaCaT Exos when treated with high dose UV-B radiation, is significantly less than that of
NG-HaCaT-Exos (Fig 19). This may be due to the high dose UV-B treatment on injured
(HG) HaCaT cells led to apoptosis and quick cell death, thereby failed package of miR-222 in
the Exos of HG-HaCaT cells.
However, the UV-B treated HG-HaCaT-Exos when co-incubated with HG-SCs, increased
cell viability, and expression of miR-222. HG-SCs were co-incubated with two
concentrations of HaCaT-Exos: 1 x 109 Exos per ml, and 2 x 109 Exos per ml. At both
concentrations, fold expressions of miR-222 in HG-SCs Treated with low UV-B dose
HaCaT-Exos show an increase in one to three folds (Fig 21), indicating that the transfer of
miR-222 from HaCaT-exos is successful and the same had been noticed in the group treated
with high dose UV-B HaCaT-Exos. Further summarized data (Fig 22) of MTT suggested that
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HG-SCs co-incubated with low dose UV-B treated HaCaT-Exos show a significant increase
in cell viability when compared to HG-SCs indicating the reduction in early apoptosis of cell
population induced by HG condition. However, when HG-SCs are treated with high dose
UV-B HaCaT-Exos (Fig 22), no significant changes were observed compared to the HG-SCs
group and justifying the content of miR-222 levs in their respective groups (Fig 21) and its
effect on cell proliferation and cell repair property in SCs.
Even though we have evidence showing that UV-B treated HaCaT Exos show beneficial
effects by transferring miR-222 into SCs. However, the enhanced effects due to miR-222
from HaCaT-Exos remain unclear as an inhibitor of miR-222 was not employed here to
determine the enhanced effect exerted was solely due to miR-222 or there were other factors
responsible for the same, which leave us with more research to conduct about one of the
extracellular particles.
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CONCLUSION
Our data for this study demonstrates that the HaCaT-Exos released in a time-dependent and
dose-dependent manner when treated with UV-B radiation. Cell viability of HaCaT cells is
reduced as the dose of UV-B radiation increases indicating dose-dependent effect, and low
dose UV-B treatment is chosen based on exosome release rate and comparatively less cell
death percentage. HG injury to SCs leads to an increase in cell damage and apoptosis.
However, the treatment with low dose UV-B treated HaCaT-Exos resulted in reduced
apoptosis by the transferred miR-222 from HaCaT cells to SCs via exosomes, thus suggesting
that UV-B treated HaCaT-Exos protect the SCs from HG injury. And the major pathways for
the mechanism of HaCaT-Exos in SCs are endocytosis which is dominant among clathrinmediated endocytosis, caveolin-dependent endocytosis, and macropinocytosis.
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